Fig 1.
Immunochromatographic test containing the 2B2t recombinant antigen (A) or hydatid fluid (B) in the test line. Two positive tests are shown in the Fig 1, control line; 2, test line. C, schematic representation of the immunochromatograpic strip and its components.
Table 1.
Demographic and clinical characteristics of 253 patients with CE.
Fig 2.
Flow chart showing the participants (cystic echinococcosis patients) in the study.
1Patients receiving surgery or percutaneous treatment before the collection of the first serum sample. 2Patients with only one serum sample.
Table 2.
Sensitivity, specificity and cross-reactivity of the ELISA and IC tests.
Table 3.
Sensitivity of the serological tests according to different clinical characteristics.
Fig 3.
Percentage of positive sera (Y axis) against hydatid fluid (black line), B2t (dashed line) and 2B2t (dotted line) recombinant antigens in ELISA.
The percentage was calculated at different time intervals after treatment (years, X axis) for patients subjected to surgery or aspiration and cured (A) or non-cured (B), subjected to drug treatment and with good response (C) or poor response (D), and at different time intervals for patients in watch and wait (E). In (B), the trend line is coincident for the B2t and 2B2t antigens.
Table 4.
Progression to negativity by treatment outcome (cured vs. non-cured patients) among patients who underwent surgical intervention or percutaneous treatment and classified as positive at baseline (time at first test available).
Table 5.
Progression to negativity by treatment response (good vs. poor) among patients who underwent drug treatment and classified as positive at baseline (time at first test available).
Table 6.
Progression to negativity by treatment group (drug1 and watch-wait) among patients who were positive at baseline (time at first test available).
Table 7.
Comparison of the SI of patients with CE4 cysts in non-treated patients and under drug treatment against hydatid fluid, B2t and 2B2t in ELISA.